Previous 10 | Next 10 |
Gainers: ReTo Eco-Solutions (RETO) +93%.Celsion (CLSN) +62%.Rodgers Silicon Valley Acquisition (RSVA) +49%.Taoping (TAOP) +44%.RealNetworks (RNWK) +32%.Cooper Tire & Rubber (CTB) +30%.MICT (MICT) +26%.Conformis (CFMS) +26%.ATIF Holdings (ATIF) +25%.Vuzix (VUZI) +23%.Losers:...
Gainers: Celsion (CLSN) +54%, SunLink Health Systems (SSY) +27%, Citius Pharmaceuticals (CTXR) +26%, Can-Fite BioPharma (CANF) +19%, Aesthetic Medical International Holdings Group (AIH) +18%.Losers: Otonomy (OTIC) -43%, Brainstorm Cell Th...
Otonomy (OTIC) -51% after Otividex fails late-stage Ménière’s disease study.Ebix (EBIX) -32% as auditor resigns after flagging material weakness.Energous (WATT) -20%.MoneyGram International (MGI) -17% on Q4 earnings.Petroleo Brasileiro S.A. - Petrobra...
Otonomy (OTIC) has lost ~50.3% in the premarket after the announcement of the clinical trial failure for OTIVIDEX in patients with Ménière’s disease.Based on topline results, the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’...
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s diseas...
Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%. For further details see: PETS, IMUX, EVGN and OTIC among after-hours movers
Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q4 2020 Earnings Call Feb 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q4 2020 Earnings Call Transcript
Otonomy, Inc. (OTIC) Q4 2020 Earnings Conference Call February 11, 2021 16:30 ET Company Participants Robert Uhl - Investor Relations David Weber - President and Chief Executive Officer Paul Cayer - Chief Financial and Business Officer Conference Call Participants Ken Cacciatore - Cowen &...
OTIVIDEX ® Phase 3 trial results in Ménière’s disease expected by end of February OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 OTO-413 Phase 1/...
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corpo...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...